FGD5

Across TCGA pan-cancer cohorts, FGD5 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of FGD5’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where FGD5 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types FGD5 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

HNSC, LSCC, and LUAD are the cancer types where FGD5 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FGD5 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	−0.576	<.001	11	view →
LSCC	All	III,IV	−1.214	<.001	9	view →
LUAD	Male	III,IV	−0.999	<.001	9	view →
CCRCC	All	II,III,IV	−0.148	.002	6	view →
PDAC	Female	All	+0.421	<.001	4	view →
OV	All	All	−0.769	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

FGD5–HNSC

Open the HNSC breakdown →